Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Active, not recruiting · Phase 2 · NCT06107413
Conditions: Unresectable Metastatic Colorectal Cancer
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 18
- Sites paid
- 20
- Planned or actual enrollment
- 280
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-400 (drug), Bevacizumab (drug), Folinic Acid (drug), Fluorouracil (drug), Irinotecan (drug)
- Dates
- Started 2023-11-12; completion 2026-12
- Results posted
- Not yet
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer. ABBV-400 is an investigational drug being developed for the treatment of unresectable metastatic colorectal cancer. Fluorouracil, folinic acid, and bevacizumab (FFB) is an approved drug for the treatment of unresectable metastatic colorectal cancer. Study doctors put the participants in groups called treatment arms. Each treatment arm receives a differen…
From ClinicalTrials.gov, last updated 2025-12-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.3M in research payments for this study in 2025 (120 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Christina S. Wu, M.D. Hematology & Oncology · Scottsdale, AZ
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Jeremy C. Jones, MD Hematology & Oncology · Jacksonville, FL
- John H. Strickler, MD Hematology & Oncology · Jacksonville, FL
- Shikha Jain, MD Hematology & Oncology · Chicago, IL
- Sunil Babu, M.D. Medical Oncology · Fort Wayne, IN
- Ashiq Masood, MD Hematology & Oncology · Indianapolis, IN
- Bert H. O'neil, MD Medical Oncology · Indianapolis, IN
- Zhaohui Jin, M.D. Medical Oncology · Rochester, MN
- Jimmy J. Hwang, MD Medical Oncology · Charlotte, NC
- Anuradha R. Thummala, MD Hematology & Oncology · Las Vegas, NV
- Heidi A. Mckean, MD Hematology & Oncology · Sioux Falls, SD
- Murtaza N. Bhuriwala, MD Medical Oncology · Tomball, TX
- Kanwal P. Raghav, M.D. Medical Oncology · Houston, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Arthur A. Winer, M.D. Medical Oncology · Fairfax, VA
- Annie K. Hung, M.D. Hematology & Oncology · Vancouver, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Inova Fairfax Hospital, VA $309,337
- Community Hospital East, IN $146,475
- Mayo Clinic Rochester $137,225
- Yale University $119,366
- Virginia Cancer Specialists PC $110,546
- Allison Curtis Kingsley $89,184
- Ut MD Anderson Cancer Center $63,319
- Mayo Clinic Hospital, AZ $60,452
- Ohsu Hospital and Clinics, OR $51,050
- Millennium Research and Clinical Development $49,001
- Duke University $26,333
- Texas Oncology PA $26,199
- Inova Loudoun Hospital, VA $24,741
- Indiana University $24,660
- The Charlotte-Mecklenburg Hospital $13,367
- Avera Mckennan Hospital & University Health Center, SD $13,018
- University of Illinois Hospital and Clinics, IL $11,168
- Fort Wayne Medical Oncology & Hemat $10,460
- Mayo Clinic Jacksonville $5,500
- Highlands Oncology Group PA $1,450
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.